

Obicetrapib+
Ezetimibe
Combination Therapy
NewAmsterdam Pharma is studying obicetrapib, a highly selective cholesteryl ester
transfer protein (CETP) inhibitor, with ezetimibe, an NPC1L1 inhibitor that blocks
intestinal reabsorption of cholesterol, as a fixed-dose combination in patients with
atherosclerotic cardiovascular disease (ASCVD), heterozygous familial
hypercholesterolemia (HeFH), or those who are CV risk equivalent, to be used alongside
maximally tolerated lipid-lowering therapies.1-3
Ongoing Combination Programs
PHASE 1
PHASE 2
PHASE 3
Cardiovascular Disease
Completed Programs
PHASE 1
PHASE 2
PHASE 3
Cardiovascular Disease


Expanded Access
1. ClinicalTrials.gov. Study of obicetrapib & ezetimibe fixed dose combination on top of maximum tolerated lipid-modifying therapies (TANDEM). NCT06005597. Last updated March 12, 2024. Accessed March 19, 2024. https://clinicaltrials.gov/study/NCT06005597 2. ClinicalTrials.gov. A CCTA imaging trial to evaluate the effect of obicetrapib/ezetimibe on coronary plaque (REMBRANDT). NCT06305559. Last updated March 12, 2024. Accessed March 19, 2024. https://clinicaltrials.gov/study/NCT06305559 3. ClinicalTrials.gov. Study to evaluate the effect of obicetrapib in combination with ezetimibe as an adjunct to HIS therapy (ROSE2). NCT05266586. Last updated July 3, 2024. Accessed July 21, 2024. https://clinicaltrials.gov/study/NCT05266586